145 related articles for article (PubMed ID: 6238589)
1. Advanced breast cancer: response to high dose oral medroxyprogesterone acetate.
Hedley D; Dalgleish A; Raghavan D; Tattersall MH; Coates A; Fox R
Aust N Z J Med; 1984 Jun; 14(3):251-4. PubMed ID: 6238589
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy with or without high-dose medroxyprogesterone acetate in oestrogen-receptor-negative advanced breast cancer. Norwegian Breast Cancer Group.
Gundersen S; Kvinnsland S; Klepp O; Lund E; Hannisdal E; Høst H
Eur J Cancer; 1992; 28(2-3):390-4. PubMed ID: 1534248
[TBL] [Abstract][Full Text] [Related]
3. Response to medroxyprogesterone acetate (NSC-26386) as secondary hormone therapy for metastatic breast cancer in postmenopausal women.
Klaassen DJ; Rapp EF; Hirte WE
Cancer Treat Rep; 1976 Mar; 60(3):251-3. PubMed ID: 1260780
[TBL] [Abstract][Full Text] [Related]
4. Oral high-dose medroxyprogesterone acetate versus tamoxifen. A randomized crossover trial in postmenopausal patients with advanced breast cancer.
van Veelen H; Willemse PH; Tjabbes T; Schweitzer MJ; Sleijfer DT
Cancer; 1986 Jul; 58(1):7-13. PubMed ID: 2939943
[TBL] [Abstract][Full Text] [Related]
5. High dose versus low dose medroxyprogesterone acetate: a randomized trial in advanced breast cancer.
Gallagher CJ; Cairnduff F; Smith IE
Eur J Cancer Clin Oncol; 1987 Dec; 23(12):1895-900. PubMed ID: 2963746
[TBL] [Abstract][Full Text] [Related]
6. Oral medroxyprogesterone acetate in the treatment of metastatic breast cancer.
Hortobagyi GN; Buzdar AU; Frye D; Yap HY; Hug V; Pinnamaneni K; Fraschini G; Halvorson HC; Blumenschein GR
Breast Cancer Res Treat; 1985; 5(3):321-6. PubMed ID: 3161565
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial of low- versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer.
Cavalli F; Goldhirsch A; Jungi F; Martz G; MermillodB ; Alberto P
J Clin Oncol; 1984 May; 2(5):414-9. PubMed ID: 6233398
[TBL] [Abstract][Full Text] [Related]
8. [Effects of high-dose medroxyprogesterone acetate in advanced breast cancer, with special reference to prior endocrine therapy and hormone receptors].
Nomura Y; Tashiro H; Hisamatsu K; Toi M
Gan To Kagaku Ryoho; 1988 Mar; 15(3):513-8. PubMed ID: 2964811
[TBL] [Abstract][Full Text] [Related]
9. High-dose medroxyprogesterone acetate (MPA) treatment in advanced breast cancer. A review.
Ganzina F
Tumori; 1979 Oct; 65(5):563-85. PubMed ID: 390798
[TBL] [Abstract][Full Text] [Related]
10. Clinical trial of high-dose oral medroxyprogesterone acetate in the treatment of metastatic breast cancer and review of the literature.
Davila E; Vogel CL; East D; Cairns V; Hilsenbeck S
Cancer; 1988 Jun; 61(11):2161-7. PubMed ID: 2966667
[TBL] [Abstract][Full Text] [Related]
11. A randomized comparison of megestrol acetate (MA) and medroxyprogesterone acetate (MPA) in patients with advanced breast cancer.
Willemse PH; van der Ploeg E; Sleijfer DT; Tjabbes T; van Veelen H
Eur J Cancer; 1990 Mar; 26(3):337-43. PubMed ID: 2141491
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate in advanced breast cancer patients.
Etienne MC; Milano G; Frenay M; Renee N; Francois E; Thyss A; Schneider M; Namer M
J Clin Oncol; 1992 Jul; 10(7):1176-82. PubMed ID: 1535103
[TBL] [Abstract][Full Text] [Related]
13. Treatment of breast cancer with medroxyprogesterone acetate.
Muggia FM; Cassieth PA; Ochoa M; Flatow FA; Gellhorn A; Hyman GA
Ann Intern Med; 1968 Feb; 68(2):328-37. PubMed ID: 4306126
[TBL] [Abstract][Full Text] [Related]
14. High-dose medroxyprogesterone acetate in advanced breast cancer. Clinical and pharmacokinetic study with a combined oral and intramuscular regimen.
Becher R; Miller AA; Höffken K; Gerhold U; Hirche H; Schmidt CG
Cancer; 1989 May; 63(10):1938-43. PubMed ID: 2522811
[TBL] [Abstract][Full Text] [Related]
15. Oral route administration of medroxyprogesterone acetate (MAP) at high doses in the treatment of advanced breast cancer: clinical results.
Guarnieri A; Tucci E; D'Aniello C; Carli A; Mariani L; De Stefano A; Nardi P
Chemioterapia; 1984 Oct; 3(5):320-3. PubMed ID: 6241848
[TBL] [Abstract][Full Text] [Related]
16. High dose medroxyprogesterone acetate (MPA) treatment in metastatic carcinoma of the breast: a dose-response evaluation.
Cuna GR; Calciati A; Strada MR; Bumma C; Campio L
Tumori; 1978 Apr; 64(2):143-9. PubMed ID: 354147
[TBL] [Abstract][Full Text] [Related]
17. Steroid hormone receptors and response to high-dose medroxyprogesterone acetate in advanced breast cancer.
Nomura Y; Tashiro H; Hisamatsu K; Shinozuka K
Anticancer Res; 1988; 8(4):647-51. PubMed ID: 2972248
[TBL] [Abstract][Full Text] [Related]
18. Oral versus im administration of high-dose medroxyprogesterone acetate in pretreated patients with advanced breast cancer.
Beex L; Burghouts J; van Turnhout J; Breed W; Hillen H; Holdrinet A; Boetius G; Hoogendoorn G; Doesburg W; Verhulst M
Cancer Treat Rep; 1987 Dec; 71(12):1151-6. PubMed ID: 3690524
[TBL] [Abstract][Full Text] [Related]
19. Oral versus intramuscular high-dose medroxyprogesterone acetate (HD-MPA) in advanced breast cancer. A randomized study of the Belgian Society of Medical Oncology.
Paridaens R; Becquart D; Michel J; Vanderlinden B; Longueville J; Majois F; Beauduin M; Focan C; Wildiers J; Bernheim J
Anticancer Res; 1986; 6(5):1089-94. PubMed ID: 2948441
[TBL] [Abstract][Full Text] [Related]
20. [Oral high-dose medroxyprogesterone acetate (MPA) in the treatment of advanced and recurrent breast cancer: a dose-response evaluation].
Tominaga T; Izuo M; Nomura Y; Kubo K; Abe O; Enomoto K; Takatani O
Gan To Kagaku Ryoho; 1982 Nov; 9(11):1994-2004. PubMed ID: 6223590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
